title: Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase.
abstract: Previously, we observed in a rat model that intravenous administration of intramuscular immunoglobulin preparations induced a long-lasting hypotension, which appeared to be associated with the presence of IgG polymers and dimers in the preparations, but unrelated to complement activation. We found evidence that this hypotensive response is mediated by platelet-activating factor (PAF) produced by macrophages. In this study, we compared the vasoactive effects of 16 intravenous immunoglobulin (IVIG) products from 10 different manufacturers, in anesthetized rats. Eight of the IVIG preparations showed no hypotensive effects (less than 15% decrease), whereas the other 8 had relatively strong effects (15%-50% decrease). The hypotensive effects correlated with the IgG dimer content of the preparations. Pretreatment of the rats with recombinant PAF acetylhydrolase completely prevented the hypotensive reaction on IVIG infusion, and administration after the onset of hypotension resulted in normalization of the blood pressure. We also observed PAF production on in vitro incubation of human neutrophils with IVIG, which could be blocked by anti-Fcgamma receptor antibodies. This indicates that induction of PAF generation may also occur in a human system. Our findings support the hypothesis that the clinical side effects of IVIG in patients may be caused by macrophage and neutrophil activation through interaction of IgG dimers with Fcgamma receptors. Because phagocyte activation may also lead to the release of other inflammatory mediators, recombinant PAF acetylhydrolase (rPAF-AH) provides a useful tool to determine whether PAF plays a role in the clinical side effects of IVIG. If so, rPAF-AH can be used for the treatment of those adverse reactions. (Blood. 2000;95:1856-1861)
authors.affiliation: CLB, Amsterdam, The Netherlands. w_bleeker@clb.nl
authors.forename: W K
authors.initials: WK
authors.lastname: Bleeker
authors.forename: J L
authors.initials: JL
authors.lastname: Teeling
authors.forename: A J
authors.initials: AJ
authors.lastname: Verhoeven
authors.forename: G M
authors.initials: GM
authors.lastname: Rigter
authors.forename: J
authors.initials: J
authors.lastname: Agterberg
authors.forename: A T
authors.initials: AT
authors.lastname: Tool
authors.forename: A H
authors.initials: AH
authors.lastname: Koenderman
authors.forename: T W
authors.initials: TW
authors.lastname: Kuijpers
authors.forename: C E
authors.initials: CE
authors.lastname: Hack
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000818:Animals; D019281:Dimerization; D004355:Drug Stability; D005260:Female; D006801:Humans; D007022:Hypotension / Q000209:etiology* / Q000517:prevention & control; D007074:Immunoglobulin G / Q000494:pharmacology / Q000633:toxicity*; D016756:Immunoglobulins, Intravenous / Q000633:toxicity*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010741:Phospholipases A / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D017452:Receptors, IgG / Q000037:antagonists & inhibitors / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D010972:Platelet Activating Factor; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase